Sponsor or institution

Clinical trials and research at RemeGen Co., Ltd.

• 21Clinical trials
• 1Country

Newest trials

All recruiting trials (21)

• RC288 cancer treatment study for solid tumors

  This trial tests RC288 to see if it is safe and tolerable and whether it works at a recommended dose in adults with solid tumors.

  Recruiting at 4 sites Phase 1/2 RemeGen Co., Ltd. · Hunan, Changsha and 13 other locations · NCT07537881

• RC148 plus chemotherapy as first-line treatment for unresectable or metastatic colorectal cancer

  This study tests RC148 with standard chemotherapy as the first treatment for people with unresectable or metastatic colorectal cancer to see if it helps more than current therapy.

  Recruiting at 19 sites Phase 2/3 RemeGen Co., Ltd. · Beijing, Beijing Municipality and 18 other locations · NCT07462143

• RC148 plus platinum chemotherapy versus tislelizumab plus platinum chemotherapy for first-line squamous non-small cell lung cancer

  This study tests whether RC148 with carboplatin and paclitaxel works better than tislelizumab with the same chemotherapy for people with newly diagnosed advanced or metastatic squamous non-small cell lung cancer who have not had prior systemic treatment.

  Recruiting at 78 sites Phase 3 RemeGen Co., Ltd. · Hefei, Anhui and 77 other locations · NCT07416474

• Disitamab vedotin plus trastuzumab and tislelizumab versus chemotherapy plus trastuzumab (± pembrolizumab) for HER2‑high advanced gastric or gastroesophageal junction adenocarcinoma

  This trial tests whether combining disitamab vedotin with trastuzumab and the immunotherapy tislelizumab works better than standard chemotherapy with trastuzumab (with or without pembrolizumab) as first‑line treatment for people with HER2‑high advanced gastric or gastroesophageal junction cancer.

  Recruiting Phase 3 RemeGen Co., Ltd. · Beijing, BJ-Beijing · NCT07315750

• Telitacicept for ocular myasthenia gravis

  This trial will test whether telitacicept can reduce eye muscle weakness in people aged 12 to 80 with ocular myasthenia gravis who are on stable standard treatment.

  Recruiting Phase 3 RemeGen Co., Ltd. · Beijing, Beijing Municipality · NCT07249632

• RC278 treatment for people with solid tumors.

  This trial will test whether RC278 is safe and can shrink measurable solid tumors in adults.

  Recruiting at 39 sites Phase 1/2 RemeGen Co., Ltd. · Beijing, Beijing Municipality and 38 other locations · NCT07105215

• RC108 plus Furmonertinib as first-line treatment for EGFR-mutated, MET-positive advanced NSCLC

  This trial tests whether adding RC108 to Furmonertinib works better than Furmonertinib alone for adults with EGFR-mutated, MET-positive unresectable locally advanced or metastatic non-small cell lung cancer.

  Recruiting at 34 sites Phase 2 RemeGen Co., Ltd. · Beijing and 33 other locations · NCT06962865

• Combining Disitamab Vedotin with RC148 for treating HR-negative, HER2-low breast cancer

  This study is testing if a new combination of two treatments can help people with hard-to-treat HR-negative, HER2-low breast cancer feel better compared to standard options.

  Recruiting Phase 2 RemeGen Co., Ltd. · Beijing, Beijing Municipality · NCT06642545

• Evaluating a new treatment for HR-positive, HER2-low breast cancer

  This study is testing a new treatment combining Disitamab Vedotin and Toripalimab with chemotherapy to see if it helps people with HR-positive, HER2-low breast cancer before surgery.

  Recruiting Phase 2 RemeGen Co., Ltd. · Shanghai, Fudan University Shanghai Cancer Center · NCT06389006

• Evaluating a new treatment for high-risk bladder cancer that expresses HER2

  This study is testing a new treatment for high-risk bladder cancer that shows a specific protein called HER2 to see if it is safe and effective for patients.

  Recruiting at 2 sites Phase 1/2 RemeGen Co., Ltd. · Guangzhou, Guangdong and 5 other locations · NCT06378242

• Neoadjuvant treatment for HR-negative, HER2 low-expressing breast cancer

  This study is testing a new combination treatment for people with HR-negative, HER2 low-expressing breast cancer to see if it helps them respond better than standard chemotherapy.

  Recruiting Phase 2 RemeGen Co., Ltd. · Changsha, Hunan and 4 other locations · NCT06227117

• Combining Disitamab Vedotin and Cadonilimab for HER2-expressing Gastric Cancer

  This study is testing if combining two treatments, Disitamab Vedotin and Cadonilimab, can help people with advanced gastric cancer that has not responded to earlier treatments.

  Recruiting at 5 sites Phase 2/3 RemeGen Co., Ltd. · Beijing, Beijing Municipality and 11 other locations · NCT06221748

• Combination therapy for HER2-positive breast cancer

  This study tests a new combination of treatments for people with HER2-positive breast cancer to see if it helps them respond better before surgery.

  Recruiting Phase 2 RemeGen Co., Ltd. · Shanghai, Shanghai Municipality · NCT06178159

• Treatment for recurrent or metastatic cervical cancer using RC48-ADC and Zimberelimab

  This study is testing a new combination treatment of RC48-ADC and Zimberelimab for patients with recurrent or metastatic cervical cancer that has HER2 expression and hasn't responded to previous platinum-based therapies.

  Recruiting Phase 2 RemeGen Co., Ltd. · Bengbu, Anhui and 11 other locations · NCT06155396

• Combination therapy for advanced gastric cancer

  This study is testing a new combination treatment for advanced gastric cancer to see if it works better than the usual options for patients with a specific type of the disease.

  Recruiting Phase 2 RemeGen Co., Ltd. · Beijing, Beijing Municipality and 10 other locations · NCT06155383

• Testing RC148 for advanced solid tumors

  This study is testing a new treatment called RC148 to see if it can safely help people with advanced solid tumors, either on its own or with other therapies.

  Recruiting at 31 sites Phase 1/2 RemeGen Co., Ltd. · Anhui and 30 other locations · NCT06016062

• Treatment for high-risk non-muscle-invasive bladder cancer

  This study is testing a new treatment combining RC48-ADC and gemcitabine for people with high-risk non-muscle-invasive bladder cancer who haven't had BCG treatment or didn't respond to it.

  Recruiting Phase 2 RemeGen Co., Ltd. · Beijing, Beijing Municipality · NCT05943379

• Combining Disitamab Vedotin with Radiotherapy for HER2 Positive Solid Tumors

  This study is testing if a new drug combined with radiation can help people with certain hard-to-treat tumors that have HER2 and who can't or don't want to use standard chemotherapy.

  Recruiting Phase 1 RemeGen Co., Ltd. · Jinan, Shandong · NCT05940896

• Combination treatment for advanced urothelial carcinoma

  This study is testing a new combination treatment for advanced bladder cancer to see if it works better than chemotherapy alone for patients who haven't received treatment before.

  Recruiting at 2 sites Phase 3 RemeGen Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT05302284

• Testing RC118 for advanced solid tumors

  This study is testing a new treatment called RC118 for people with advanced solid tumors that have a specific marker to see if it is safe and effective.

  Recruiting Phase 1/2 RemeGen Co., Ltd. · Shanghai, Shanghai Municipality and 1 other locations · NCT05205850

• Treatment for advanced breast cancer with low HER2 expression

  This study is testing a new treatment called RC48-ADC to see if it works better than standard options for people with advanced breast cancer that has low HER2 levels.

  Recruiting Phase 3 RemeGen Co., Ltd. · Beijing, Beijing Municipality · NCT04400695

Quick answers

How many clinical trials run by RemeGen Co., Ltd. are recruiting right now?

21, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 8, Phase 1/2: 5, Phase 3: 5, Phase 2/3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →